Aldosterone and the Mineralocorticoid Receptor: Risk Factors for Cardiometabolic Disorders

Rajesh Garg, Gail K. Adler

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


Preclinical studies have convincingly demonstrated a role for the mineralocorticoid receptor (MR) in adipose tissue physiology. These studies show that increased MR activation causes adipocyte dysfunction leading to decreased production of insulin-sensitizing products and increased production of inflammatory factors, creating an environment conducive to metabolic and cardiovascular disease. Accumulating data also suggest that MR activation may be an important link between obesity and metabolic syndrome. Moreover, MR activation may mediate the pathogenic consequences of metabolic syndrome. Recent attempts at reversing cardiometabolic damage in patients with type 2 diabetes using MR antagonists have shown promising results. MR antagonists are already used to treat heart failure where their use decreases mortality and morbidity over and above the use of traditional therapies alone. However, more data are needed to establish the benefits of MR antagonists in diabetes, obesity, and metabolic syndrome.

Original languageEnglish (US)
Article number52
JournalCurrent Hypertension Reports
Issue number7
StatePublished - Jul 13 2015
Externally publishedYes


  • Aldosterone
  • Cardiometabolic risk
  • Cardiovascular disease
  • Diabetes
  • Metabolic syndrome
  • Mineralocorticoid receptor
  • Obesity

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Aldosterone and the Mineralocorticoid Receptor: Risk Factors for Cardiometabolic Disorders'. Together they form a unique fingerprint.

Cite this